ADMA Biologics Reports Q1 2026 Earnings with Mixed Performance Across Product Lines
ADMA Biologics (ADMA) reported Q1 2026 earnings with total revenue of $114.5 million, flat compared to the prior year. ASCENIV revenue rose 28% to $97.5 million, while BIVIGAM revenue fell 54% to $15.4 million. The company achieved a 71% gross margin and 24% growth in adjusted EBITDA.
Tickers: $ADMA
Topics: cash_flow ebitda gross_profit net_income revenue share_repurchases